




1/113

Figure 1A


2/113

Figure 1B


3/113

Figure 2


4/113

Figure 3


5/113

Figure 4


6/113

Figure 5


7/113

Figure 6


8/113

Figure 7


9/113

Figure 8


10/113

Figure 9


11/113

Figure 10


12/113

Figure 11


13/113

Figure 12


14/113

Figure 13


15/113

Figure 14


16/113

Figure 15


17/113

Figure 16

18/113

Figure 17

19/113

Figure 18

20/113



Figure 19


Figure 20



22/113

Figure 21A

Cell survival in Plasma and Plasma Products



23/113

Figure 21B

Neurogenesis in Plasma and Plasma Products





Figure 22A




25/113


Figure 22B

26/113

Figure 22C




27/113


Figure 23

b - BrdU
 X - Old Plasma or Saline injections


28/113

Figure 24


Analysis 48h post last dose

Analysis 21 days
post last dose


29/113

Figure 25


Analysis 48h post last dose

Analysis 21 days
post last dose


30/113

Figure 26


31/113

Figure 27


32/113

Figure 28


33/113

Figure 29


34/113

Figure 30


35/113

Figure 31A


36/113

Figure 31B

37/113


Figure 32

38/113


Figure 33**DG-6mo**

39/113


Figure 34




40/113

Figure 35A


41/113

Figure 35B


42/113

Figure 36A


43/113

Figure 36B


44/113

Figure 37A


45/113

Figure 37B


46/113

Figure 37C


47/113

Figure 38A


48/113

Figure 38B


49/113

Figure 38C


50/113

Figure 38D


51/113

Figure 39A

52/113


Figure 39B

53/113


Figure 40

Darker areas indicate areas of increased signal.


54/113

Figure 41A


55/113

Figure 41B**B**


56/113

Figure 41C


57/113

Figure 41D


58/113

Figure 41E


59/113

Figure 42A


60/113

Figure 42B


61/113

Figure 43A


62/113

Figure 43B


63/113

Figure 44


64/113

Figure 45A

65/113


Figure 45B

66/113


Figure 46

67/113

Figure 47A



68/113

Figure 47B

69/113





Figure 47C

Figure 48A


71/113

Figure 48B


72/113

Figure 48C


73/113

Figure 48D


74/113

Figure 48E


75/113

Figure 48F


76/113

Figure 49


77/113

Figure 50


78/113

Figure 51


79/113

Figure 52A

80/113


Figure 52B

81/113

Figure 53


82/113

Figure 54A




83/113

Figure 54B




84/113


Figure 55A




85/113

Figure 55B

86/113

Figure 55C

87/113

Figure 55D

88/113

Figure 56A







Figure 56B




90/113

Figure 57A


91/113

Figure 57B


92/113

Figure 58A


93/113

Figure 58B


94/113

Figure 59


95/113

Figure 60A


96/113

Figure 60B


97/113

Figure 61A


98/113

Figure 61B


99/113

Figure 62A


100/113

Figure 62B


101/113

Figure 63


102/113

Figure 64A


103/113

Figure 64B


104/113

Figure 65A


105/113

Figure 65B


106/113

Figure 66


107/113

Figure 67


108/113

Figure 68


109/113

Figure 69A


110/113

Figure 69B

111/113

Figure 70A

112/113

Figure 70B

113/113

Figure 71

	100 mL	250 mL
N (randomized)	27	26
Age, y (mean, SD)	74 (6.0)	74 (7.7)
Women	18	14
Men	9	12
ADAS-Cog, mean (SD)	24 (13)	18 (10)
ADCS-ADL, mean (SD)	59 (13)	62 (14)
CDR-SB, mean (SD)	6.3 (3.0)	4.9 (3.0)
APOE4 carriers	9	10